tiprankstipranks
Artelo Biosciences announces new data on novel non-opioid treatment for OA pain
The Fly

Artelo Biosciences announces new data on novel non-opioid treatment for OA pain

Artelo Biosciences (ARTL) announced new data being presented today on ART26.12, Artelo’s lead clinical Fatty Acid Binding Protein 5, FABP5, inhibitor, in osteoarthritis, OA, pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium in New York. This evidence adds OA pain to the list of pain types such as neuropathic and cancer bone pain where ART26.12 has shown potential as an analgesic with a novel mechanism of action.

Pick the best stocks and maximize your portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App